It should be emphasized that the study cohort comprised of a substantial proportion of patients harboring adverse cytogenetic anomalies (50%), with a quarter of patients with TP53 or IDH1/2 mutations and secondary AML. Here, TP53 is linked to acute myeloid leukemia.